An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques

Nature Communications

Volumn 7, Issue , 2016, Pages

  Fredman, Gabrielle ^a,b   Hellmann, Jason ^c   Proto, Jonathan D ^a   Kuriakose, George ^a   Colas, Romain A ^c   Dorweiler, Bernhard ^d   Connolly, E Sander ^a   Solomon, Robert ^a   Jones, David M ^b   Heyer, Eric J ^a   Spite, Matthew ^c   Tabas, Ira ^a  

^a NewYork Presbyterian Hospital   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; AUTACOID; DOCOSAHEXAENOIC ACID; LEUKOTRIENE B4; RESOLVIN D1; UNCLASSIFIED DRUG;

DISEASE SEVERITY; IMMUNE RESPONSE; LIPID; MASS SPECTROMETRY; MOLECULAR ANALYSIS; OXIDATION; PROTEIN; RODENT; SENSORY SYSTEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID ATHEROSCLEROSIS; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CONTROLLED STUDY; DISEASE COURSE; EFFEROCYTOSIS; FAT INTAKE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; LOW DENSITY LIPOPROTEIN RECEPTOR KO MOUSE; MALE; MOUSE; NECROSIS; NONHUMAN; OXIDATIVE STRESS;

MUS;

EID: 84988603167     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12859     Document Type: Article

References (63)

1. Merched, A. J., Ko, K., Gotlinger, K. H., Serhan, C. N. & Chan, L. Atherosclerosis: Evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J. 22, 3595-3606 (2008).
2. Tabas, I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10, 36-46 (2010).
3. Libby, P., Tabas, I., Fredman, G. & Fisher, E. A. Inflammation and its resolution as determinants of acute coronary syndromes. Circ. Res. 114, 1867-1879 (2014).
4. Viola, J. & Soehnlein, O. Atherosclerosis-a matter of unresolved inflammation. Semin. Immunol. 27, 184-193 (2015).
5. Serhan, C. N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92-101 (2014).
6. Fredman, G., Li, Y., Dalli, J., Chiang, N. & Serhan, C. N. Self-limited versus delayed resolution of acute inflammation: Temporal regulation of pro-resolving mediators and microRNA. Sci. Rep. 2, 639 (2012).
7. Chiang, N. et al. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484, 524-528 (2012).
8. Karp, C. L. et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 5, 388-392 (2004).
9. Levy, B. D. et al. Diminished lipoxin biosynthesis in severe asthma. Am. J. Respir. Crit. Care Med. 172, 824-830 (2005).
10. Fredman, G. et al. Impaired phagocytosis in localized aggressive periodontitis: Rescue by resolvin e1. PLoS ONE 6, e24422 (2011).
11. Virmani, R., Burke, A. P., Farb, A. & Kolodgie, F. D. Pathology of the vulnerable plaque. J. Am. Coll. Cardiol. 47, C13-C18 (2006).
12. Schrijvers, D. M., DeMeyer, G. R., Kockx, M. M., Herman, A. G. &Martinet, W. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25, 1256-1261 (2005).
13. Spanbroek, R. et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl Acad. Sci. USA 100, 1238-1243 (2003).
14. Brock, T. G., Maydanski, E., McNish, R. W. & Peters-Golden, M. Colocalization of leukotriene a4 hydrolase with 5-lipoxygenase in nuclei of alveolar macrophages and rat basophilic leukemia cells but not neutrophils. J. Biol. Chem. 276, 35071-35077 (2001).
15. Luo, M., Jones, S. M., Peters-Golden, M. & Brock, T. G. Nuclear localization of 5-lipoxygenase as a determinant of leukotriene B4 synthetic capacity. Proc. Natl Acad. Sci. USA 100, 12165-12170 (2003).
16. Fredman, G. et al. Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway. Proc. Natl Acad. Sci. USA 111, 14530-14535 (2014).
17. Finn, A. V., Nakano, M., Narula, J., Kolodgie, F. D. & Virmani, R. Concept of vulnerable/unstable plaque. Arterioscler. Thromb. Vasc. Biol. 30, 1282-1292 (2010).
18. Channon, K. M. Oxidative stress and coronary plaque stability. Arterioscler. Thromb. Vasc. Biol. 22, 1751-1752 (2002).
19. Li, G., Scull, C., Ozcan, L. & Tabas, I. NADPH oxidase links endoplasmic reticulum stress, oxidative stress, and PKR activation to induce apoptosis. J. Cell Biol. 191, 1113-1125 (2010).
20. Brooks, C. J., Harland, W. A. & Steel, G. Squalene, 26-hydroxycholesterol and 7-ketocholesterol in human atheromatous plaques. Biochim. Biophys. Acta 125, 620-622 (1966).
21. He, B. J. et al. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat. Med. 17, 1610-1618 (2011).
22. Erickson, J. R. et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 133, 462-474 (2008).
23. Serhan, C. N. et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J. Exp. Med. 206, 15-23 (2009).
24. Krishnamoorthy, S., Recchiuti, A., Chiang, N., Fredman, G. & Serhan, C. N. Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am. J. Pathol. 180, 2018-2027 (2012).
25. Thorp, E., Cui, D., Schrijvers, D. M., Kuriakose, G. & Tabas, I. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe mice. Arterioscler. Thromb. Vasc. Biol. 28, 1421-1428 (2008).
26. Serhan, C. N. et al. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J. Immunol. 171, 6856-6865 (2003).
27. Fredman, G. et al. Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci. Transl. Med. 7, 275ra220 (2015).
28. Hasturk, H. et al. Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arterioscler. Thromb. Vasc. Biol. 35, 1123-1133 (2015).
29. Drechsler, M. et al. Annexin A1 counteracts chemokine-induced arterial myeloid cell recruitment. Circ. Res. 116, 827-835 (2015).
30. Kusters, D. H. et al. Pharmacological Treatment with annexin A1 reduces atherosclerotic plaque burden in LDLR mice on western type diet. PLoS ONE 10, e0130484 (2015).
31. Brezinski, D. A., Nesto, R. W. & Serhan, C. N. Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy. Circulation 86, 56-63 (1992).
32. Qiu, H. et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc. Natl Acad. Sci. USA 103, 8161-8166 (2006).
33. Heller, E. A. et al. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 112, 578-586 (2005).
34. Haeggstrom, J. Z. & Funk, C. D. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem. Rev. 111, 5866-5898 (2011).
35. Ho, K. J. et al. Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am. J. Pathol. 177, 2116-2123 (2010).
36. Elajami, T. K. et al. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J. 30, 2792-2801 (2016).
37. Poeckel, D. & Funk, C. D. The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease. Cardiovasc. Res. 86, 243-253 (2010).
38. Merched, A. J., Serhan, C. N. & Chan, L. Nutrigenetic disruption of inflammation-resolution homeostasis and atherogenesis. J. Nutrigenet. Nutrigenomics 4, 12-24 (2011).
39. Cyrus, T. et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J. Clin. Invest. 103, 1597-1604 (1999).
40. Wan, J. B. et al. Endogenously decreasing tissue n-6/n-3 fatty acid ratio reduces atherosclerotic lesions in apolipoprotein E-deficient mice by inhibiting systemic and vascular inflammation. Arterioscler. Thromb. Vasc. Biol. 30, 2487-2494 (2010).
41. Dwyer, J. H. et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N. Engl. J. Med. 350, 29-37 (2004).
42. ORIGIN Trial Investigators et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N. Engl. J. Med. 367, 309-318 (2012).
43. Norris, P. C., Gosselin, D., Reichart, D., Glass, C. K. & Dennis, E. A. Phospholipase A2 regulates eicosanoid class switching during inflammasome activation. Proc. Natl Acad. Sci. USA 111, 12746-12751 (2014).
44. Lehmann, C. et al. Lipoxin and resolvin biosynthesis is dependent on 5-lipoxygenase activating protein. FASEB J. 29, 5029-5043 (2015).
45. Titos, E. et al. Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: Role of Kupffer cells. J. Leukoc. Biol. 78, 871-878 (2005).
46. Hill, E., Maclouf, J., Murphy, R. C. & Henson, P. M. Reversible membrane association of neutrophil 5-lipoxygenase is accompanied by retention of activity and a change in substrate specificity. J. Biol. Chem. 267, 22048-22053 (1992).
47. Elias, I. et al. Alox5ap overexpression in adipose tissue leads to LXA4 production and protection against diet-induced obesity and insulin resistance. Diabetes 65, 2139-2150 (2016).
48. Rao, N. L. et al. Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. J. Pharmacol. Exp. Ther. 321, 1154-1160 (2007).
49. Hasturk, H. et al. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J. Immunol. 179, 7021-7029 (2007).
50. Norling, L. V. et al. Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis. JCI Insight 1, e85922 (2016).
51. Kain, V. et al. Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function. J. Mol. Cell. Cardiol. 84, 24-35 (2015).
52. Borgeson, E. et al. Lipoxin A(4) and benzo-lipoxin A(4) attenuate experimental renal fibrosis. FASEB J. 25, 2967-2979 (2011).
53. Yatomi, M. et al. 17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice. Physiol. Rep. 3, e12628 (2015).
54. Miyahara, T. et al. D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB J. 27, 2220-2232 (2013).
55. Krishnamoorthy, S. et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc. Natl Acad. Sci. USA 107, 1660-1665 (2010).
56. Lee, H. N. & Surh, Y. J. Resolvin D1-mediated NOX2 inactivation rescues macrophages undertaking efferocytosis from oxidative stress-induced apoptosis. Biochem. Pharmacol. 86, 759-769 (2013).
57. Perretti, M. et al. Endogenous lipid-and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat. Med. 8, 1296-1302 (2002).
58. Kamaly, N. et al. Targeted interleukin-10 nanotherapeutics developed with a microfluidic chip enhance resolution of inflammation in advanced atherosclerosis. ACS Nano 10, 5280-5292 (2016).
59. Harmon, E. Y. et al. Anti-inflammatory immune skewing is atheroprotective: Apoe FcgammaRIIb mice develop fibrous carotid plaques. J. Am. Heart Assoc. 3, e001232 (2014).
60. Dalli, J. & Serhan, C. N. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 120, e60-e72 (2012).
61. Timmins, J. M. et al. Calcium/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways. J. Clin. Invest. 119, 2925-2941 (2009).
62. Wang, Y., Wang, G. Z., Rabinovitch, P. S. & Tabas, I. Macrophage mitochondrial oxidative stress promotes atherosclerosis and nuclear factorkappaB-mediated inflammation in macrophages. Circ. Res. 114, 421-433 (2014).
63. Colas, R. A., Shinohara, M., Dalli, J., Chiang, N. & Serhan, C. N. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am. J. Physiol. Cell. Physiol. 307, C39-C54 (2014).